Schrodinger, Inc. (SDGR): Capital Expenditures
$1.44M
Year ended 2025-12-31
$3.40M
Trailing 12 months to 2026-06-30
-43.5%
3-year compound annual growth
-10.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.44M | -80.3% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $7.31M | -45.5% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $13.40M | +67.2% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $8.01M | +11.8% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $7.17M | +182.4% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $2.54M | +38.2% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $1.84M | n/a | 2022-02-24, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $1.44M | -80.3% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $1.90M | +5.6% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $2.00M | -66.7% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $452.0K | -75.2% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $1.55M | -19.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $28.32M | +142.2% |
| Harrow, Inc. (HROW) | 2025-12-31 | $887.0K | -44.4% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $291.0K | +781.8% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $87.0K | -75.7% |
Compare SDGR, ARVN, RCUS, LGND side by side · Screen every company in Pharmaceutical Preparations ↗